Evidence map›Paper›PMID 41199254›Full record

ArticleBMC cancer2025

Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma.

Jinhui Huang, Shoufang Tong, Jin Liu, Shushan Hua, Jie Zhang, Rajneesh Mungur, Shuai Liu, Jiugeng Feng, Bin Tang, Jianping Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinhui Huang *Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Shoufang Tong *Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, 310000, People's Republic of China.
Jin Liu *Department of Pharmacy, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Shushan HuaZhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, 310000, People's Republic of China.
Jie ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Rajneesh MungurDepartment of Neurosurgery, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Province, 310000, People's Republic of China.
Shuai LiuDepartment of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Jiugeng FengDepartment of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Bin TangDepartment of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Jianping ZengDepartment of Neurosurgery, The First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17, Nanchang, Jiangxi Province, 330006, People's Republic of China. ndyfy08300@ncu.edu.cn.

Funding

the Jiangxi Province Natural Science Foundation project No.20224BAB206066the Natural Science Foundation of Jiangxi Province, China No. 20242BAB25530the Science and Technology Planning Project of Jiangxi Province, China No. 202510252the Scientific Research Fund of Jiangxi Provincial Education Department No. GJJ200110the Youth Scientific Research Cultivation Fund of the First Affiliated Hospital of Nanchang University No. YFYPY2020
6 · The paper itself

Abstract

objectiveInvestigating the expression levels of immune checkpoint genes CD276, CD40, TNFSF14, and TNFSF9 in glioblastoma multiforme patients about copper death and patient prognosis.

methodsTranscriptional data of GBM patients were obtained from the TCGA database. LASSO Cox regression analysis was performed to identify four immune checkpoint genes (CD276, CD40, TNFSF14, and TNFSF9) associated with copper death in glioblastoma. Bioinformatics analysis was conducted to explore the correlation between the key copper death protein FDX1 and immune checkpoints. The Kaplan-Meier analysis was conducted to assess the prognosis between groups with high and low expression levels.

resultsCD276, CD40, and TNFSF14 were significantly upregulated in glioblastoma compared to adjacent normal tissues (P < 0.05), while TNFSF9 was significantly downregulated (P < 0.05). Patients with high expression of CD276, CD40, and TNFSF14 showed significantly poorer prognosis compared to those with low expression (P < 0.05). There was no statistical difference in prognosis between high and low expression groups of TNFSF9 (P > 0.05). Knockdown of CD40, CD276, and TNFSF14 significantly reduced cell viability in the A172 cell line compared to the control group (P < 0.05), while overexpression of TNFSF9 significantly reduced cell viability (P < 0.05). Similar results were observed in the U251 cell line (P < 0.05) after knockdown of CD40, CD276, and TNFSF14, as well as overexpression of TNFSF9.

conclusionThe expression levels of immune checkpoint genes CD276, CD40, and TNFSF14 related to copper death are positively correlated with the prognosis of GBM patients, while the expression level of TNFSF9 is negatively correlated with the prognosis of GBM patients. This study establishes a novel link between immune checkpoint genes and cuproptosis, bridging copper-induced cell death mechanisms with immunotherapy for glioma.

Indexed as

Brain NeoplasmsCopperGlioblastomaImmune Checkpoint Proteins4-1BB LigandB7 AntigensBiomarkers, TumorCD27 LigandCD40 AntigensCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle Aged4-1BB LigandB7 AntigensBiomarkers, TumorCD27 LigandCD40 AntigensCopperImmune Checkpoint ProteinsTNFSF14 protein, humanTNFSF9 protein, humanTumor Necrosis Factor Ligand Superfamily Member 14Tumor Necrosis Factor Receptor Superfamily, Member 9CuproptosisGlioblastomaImmune checkpointsPrognosis

Identifiers

PMID41199254
PMCPMC12590761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.